Form 4: Vir Biotechnology Executive Boosts Equity Holdings

A Vir Biotechnology executive acquired significant equity and options, while also selling shares to cover tax obligations.

Summary

• Vanina de Verneuil, EVP, General Counsel, and Corporate Secretary of Vir Biotechnology, Inc. (VIR), reported transactions related to her beneficial ownership.
• Acquired 55,000 Restricted Stock Units (RSUs) on February 22, 2026, pursuant to the Issuer's Equity Incentive Plan, at a price of $0.
• Acquired 110,000 stock options on February 22, 2026, with an exercise price of $7.56.
• Sold 4,445 shares of common stock on February 23, 2026, at a price of $7.4528 per share.
• The sale of shares was an automatic and mandatory transaction under a Rule 10b5-1 arrangement, specifically to satisfy the Issuer's tax withholding obligations in connection with the vesting of RSUs.
• Following these reported transactions, de Verneuil beneficially owns 129,799 shares of common stock and 110,000 derivative stock options.
• The stock options will vest 25% on February 22, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter.
• The reported common stock holdings include 1,034 shares acquired on November 28, 2025, through an employee stock purchase program.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a key executive is significantly increasing their long-term equity exposure through RSUs and stock options, demonstrating continued commitment to the company's future.

Positives

• Significant acquisition of 55,000 Restricted Stock Units (RSUs) and 110,000 stock options by a key executive, indicating a strong long-term commitment and confidence in the company's future prospects.
• The acquisition of equity incentives aligns the executive's interests with those of shareholders, promoting long-term value creation.

Negatives

• The sale of 4,445 shares, although for tax withholding purposes, reduces the executive's direct common stock holdings.

Industry Context

StockSavvy.ai notes that insider equity acquisitions, even when coupled with tax-related sales, often signal management's long-term belief in the company's prospects, a common occurrence in the biotechnology sector where long development cycles necessitate executive retention through equity incentives.

Comparison to Industry Standards

• StockSavvy.ai observes that the use of Rule 10b5-1 plans for tax withholding is a standard practice among executives in publicly traded companies, particularly in high-growth sectors like biotechnology, to manage equity compensation and avoid accusations of insider trading.
• The vesting schedule for stock options, with a multi-year horizon (25% after one year, then monthly over three years), aligns with typical industry standards for executive retention and performance incentives in the biotechnology sector.

Stakeholder Impact

• Shareholders: The executive's increased equity stake through RSUs and stock options aligns her financial interests with those of shareholders, potentially fostering greater long-term value creation.
• Employees: The mention of an employee stock purchase program (ESPP) indicates broader employee equity participation, which can enhance employee retention and motivation.

Next Steps

• 25% of the acquired stock options will vest and become exercisable on February 22, 2027.
• The remaining stock options will vest in 36 equal monthly installments after the initial vesting date.

Key Dates

Recommendation

The filing details routine insider transactions, including significant equity awards and a tax-related sale. While the executive's increased long-term equity exposure is a positive signal of confidence, a Form 4 alone does not provide sufficient fundamental or strategic information to warrant a strong buy or sell recommendation. A 'hold' is appropriate as it indicates no immediate negative catalysts from this specific filing, but further analysis of the company's financials and strategic direction is required for a more definitive stance.

Keywords

Vir Biotechnology, VIR, SEC Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Equity Incentive Plan, Executive Compensation, Rule 10b5-1